Geisinger CEO hired by Google to oversee healthcare push

Google has taken another prominent healthcare executive under its roof to oversee the company’s own healthcare initiatives, The Wall Street Journal reported.

David Feinberg, MD, who has served as president and CEO of Geisinger Health System since 2015, has been named to a newly created leadership role at Google. Geisinger, based in Danville, Pennsylvania, is a healthcare system that operates 13 hospital campuses and a health plan with nearly 600,000 members. It serves more than 1.5 million patients in Pennsylvania and New Jersey.

Jaewon Ryu, MD, JD, will act as interim president and CEO of Geisinger starting Dec. 1, 2018, Geisinger announced.

Google’s latest hire continues the company’s emergence in the healthcare space. Google is reportedly working on an AI-powered wellness app, among other initiatives. Google’s parent company Alphabet has also invested hundreds of millions of dollars in healthcare startups, including health insurer Oscar Health.

Feinberg will help provide strategic direction for Google's ongoing healthcare pushes, the WSJ reported. 

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.